Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by gojotv!on Mar 28, 2023 5:06pm
203 Views
Post# 35365525

RE:New FDA Proposed Guidance on AA

RE:New FDA Proposed Guidance on AADoubt it will have any impact on us... So far, Accelerated Approvals have been handed ou to techs with low response rates.
If Ruvidar shows a non-toxic, Complete response rate in the 40%+ range, it won't matter if the trial was single-arm, as clear efficacy will be demonstrated...
In fact, slowing TLT"s progress at that junctire would leave the FDA open to ridicule, if not lawsuits.
Big Pharma and the FDA have already been accused of slowing possible cancer cures. In this instance, the evidence would be clear.
No one at the FDA wants to confirm the worst rumours about its possible corruption in favour of Big Pharma.
So, I'm not worried.
GLTA real investors! 2023 is the Year of Ruvidar!


<< Previous
Bullboard Posts
Next >>